- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00811642
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be 18-70 years male or female
- Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.
- Sign informed consent form
Exclusion Criteria:
- Female participants who are pregnant or are nursing.
- Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B
- Participants with progressive nervous system diseases( excluding those IFI caused)
Participants who take the following drugs known with interference with azole antifungal preparations
- terfenadine, cisapride, and ebastine within 24 hours before entry
- astemizole at entry or within 10 days before entry
- cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry
- The drugs listed above are prohibited during the investigation
- Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate <60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.
- Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.
- Expected to take during investigation or is taking systemic antifungal treatment
- Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are >2×ULN.
- Participants expected to survive no more than 72hrs
- Participants receiving artificial aeration and will not withdraw within 24hrs
- Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.
- Prior enrollment in this study.
- History of alcohol and/or drug abuse.
- Participants cannot be compliant in investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Posaconazole
Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
|
400mg BID oral suspension for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment
Time Frame: Treatment week 12
|
EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of Invasive Fungal Infection (IFI) attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment. Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession. Stable disease: no progress in IFI attributable symptoms, if present at enrollment. Failure: deterioration in IFI attributable clinical symptoms. |
Treatment week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment
Time Frame: Treatment week 4
|
EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment. Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession. Stable disease: no progress in IFI attributable symptoms, if present at enrollment. Failure: deterioration in IFI attributable clinical symptoms. |
Treatment week 4
|
Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment
Time Frame: Treatment week 8
|
EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment. Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession. Stable disease: no progress in IFI attributable symptoms, if present at enrollment. Failure: deterioration in IFI attributable clinical symptoms. |
Treatment week 8
|
Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment
Time Frame: Treatment week 4
|
EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting fungal pathogen from a primary site previously positive. Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated. Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen. |
Treatment week 4
|
Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment
Time Frame: Treatment week 8
|
EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting fungal pathogen from a primary site previously positive. Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated. Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen. |
Treatment week 8
|
Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment
Time Frame: Treatment week 12
|
EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting fungal pathogen from a primary site previously positive. Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated. Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen. |
Treatment week 12
|
Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up
Time Frame: Follow-up week 14
|
Total number of participant deaths was assessed at the end of 2 week post-treatment follow-up (14 weeks).
The total number of deaths was compared to the number of survivors at baseline.
|
Follow-up week 14
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Bacterial Infections and Mycoses
- Infections
- Communicable Diseases
- Mycoses
- Invasive Fungal Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- 14-alpha Demethylase Inhibitors
- Trypanocidal Agents
- Posaconazole
Other Study ID Numbers
- P05551
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fungal Infection
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
People's Hospital of Zhengzhou UniversityCompletedAn Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDMInvasive Fungal InfectionChina
-
Grupo de Estudio de Infecciones en TransplantadosMerck Sharp & Dohme LLCUnknownLiver Transplantation | Fungal InfectionSpain
-
Bayside HealthMerck Sharp & Dohme LLCUnknownFungal InfectionAustralia
-
University of PittsburghSchering-PloughTerminatedFungal InfectionUnited States
-
Daping Hospital and the Research Institute of Surgery...RecruitingInvasive Fungal Infection | Neonatal Infection | Plasma AdministrationChina
-
Merck Sharp & Dohme LLCCompleted
-
University of PittsburghAstellas Pharma US, Inc.Completed
-
Ruijin HospitalMerck Sharp & Dohme LLCUnknown
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
Clinical Trials on Posaconazole
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedInvasive AspergillosisBelgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
-
Bayside HealthMerck Sharp & Dohme LLCUnknownFungal InfectionAustralia
-
Merck Sharp & Dohme LLCCompleted
-
Radboud University Medical CenterMerck Sharp & Dohme LLC; St. Antonius HospitalCompleted
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingMetastatic Triple-Negative Breast CarcinomaSingapore
-
Nissan Chemical IndustriesCompletedIntermittent Claudication | Peripheral Vascular DiseaseUnited States
-
Bambino Gesù Hospital and Research InstituteRadboud University Medical Center; University of Exeter; Consorzio per Valutazioni...RecruitingCystic Fibrosis | AspergillosisIreland, Spain, Netherlands, France, United Kingdom, Czechia, Germany, Greece, Italy, Portugal, Switzerland